Cargando…
Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan
BACKGROUND: Accelerated tumor growth during immunotherapy in pre-existing measurable lesions, hyperprogressive disease (HPD), has been reported. However, progression of non-measurable lesions and new lesions are frequently observed in patients with advanced gastric cancer (AGC). METHODS: This retros...
Autores principales: | Aoki, Masahiko, Kadowaki, Shigenori, Takahashi, Naoki, Suzuki, Takeshi, Oshima, Kotoe, Ando, Takayuki, Yamamoto, Yoshiyuki, Kawakami, Kentaro, Kito, Yosuke, Matsumoto, Toshihiko, Shimozaki, Keitaro, Miyazaki, Yasuhiro, Yamaguchi, Toshifumi, Nagase, Michitaka, Tamura, Takao, Amanuma, Yusuke, Esaki, Taito, Miura, Yuji, Akiyoshi, Kohei, Baba, Eishi, Makiyama, Akitaka, Negoro, Yuji, Nakashima, Koji, Sugimoto, Naotoshi, Nagashima, Kengo, Shoji, Hirokazu, Boku, Narikazu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813080/ https://www.ncbi.nlm.nih.gov/pubmed/36316527 http://dx.doi.org/10.1007/s10120-022-01349-y |
Ejemplares similares
-
An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)
por: Kawakami, Hisato, et al.
Publicado: (2021) -
Progression patterns and site‐specific responses in advanced gastric cancer patients treated with nivolumab
por: Kadono, Toru, et al.
Publicado: (2023) -
Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
por: Yamamoto, Shun, et al.
Publicado: (2021) -
A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy
por: Kumagai, Hozumi, et al.
Publicado: (2018) -
Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer
por: Oshima, Kotoe, et al.
Publicado: (2022)